At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 110 enrolled
Drug / intervention
CM512 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Single/Multiple Dose Escalation, Placebo-controlled Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM512 in Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 1 clinical trial evaluating CM512 and Placebo for Atopic Dermatitis. Completed, enrolled 110 participants across 1 site.
Detailed Summary
This is a randomized, double-blind, single/multiple dose escalation, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in healthy subjects and patients with moderate to severe atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
20252026
First PostedAug 2024
Enrollment StartSep 2024
Primary CompletionAug 2025
Study CompletionSep 2025
TodayJul 2026
First PostedAug 14, 2024
Enrollment StartSep 2, 2024
Primary CompletionAug 26, 2025
Study CompletionSep 12, 2025
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 1.9 years ago
Interventions
CM512biological
CM512 injection
Placebodrug
Placebo